271 related articles for article (PubMed ID: 1691750)
1. Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
Leebeek FW; Kluft C; Knot EA; Los P; Cohen AF; Six AJ
J Am Coll Cardiol; 1990 May; 15(6):1212-20. PubMed ID: 1691750
[TBL] [Abstract][Full Text] [Related]
2. Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator.
Gram J; Munkvad S; Leebeek FW; Kluft C; Jespersen J
Coron Artery Dis; 1993 Apr; 4(4):371-7. PubMed ID: 8261210
[TBL] [Abstract][Full Text] [Related]
3. Catabolic pathways for streptokinase, plasmin, and streptokinase activator complex in mice. In vivo reaction of plasminogen activator with alpha 2-macroglobulin.
Gonias SL; Einarsson M; Pizzo SV
J Clin Invest; 1982 Aug; 70(2):412-23. PubMed ID: 6178757
[TBL] [Abstract][Full Text] [Related]
4. Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.
Reed GL; Matsueda GR; Haber E
Proc Natl Acad Sci U S A; 1990 Feb; 87(3):1114-8. PubMed ID: 1689060
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
Rouy D; Anglés-Cano E
Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
[TBL] [Abstract][Full Text] [Related]
6. Regulation of streptokinase-human plasmin complex by the plasma proteinase inhibitors alpha 2-antiplasmin and alpha 2-macroglobulin is species specific and temperature dependent.
Gonias SL; Figler NL; Braud LL
Blood; 1988 Nov; 72(5):1658-64. PubMed ID: 2460159
[TBL] [Abstract][Full Text] [Related]
7. Production of the modified form of human plasminogen by alpha 2-macroglobulin-plasmin complexes.
Yamamoto J; Okamoto U; Morita S; Asada N; Yamaoka M
Jpn J Physiol; 1985; 35(6):1013-21. PubMed ID: 2422420
[TBL] [Abstract][Full Text] [Related]
8. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
9. Interaction of SK-human plasmin, SK-dog plasmin complexes with alpha 2-antiplasmin and alpha 2-macroglobulin.
Reddy KN; Cercek B; Lew AS; Ganz W
Thromb Res; 1986 Mar; 41(5):671-80. PubMed ID: 2421434
[TBL] [Abstract][Full Text] [Related]
10. alpha 2-Antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy.
Collen D; Verstraete M
Thromb Res; 1979; 14(4-5):631-9. PubMed ID: 90396
[No Abstract] [Full Text] [Related]
11. [The effect of plasmin and its complexes with alpha 2-antiplasmin and alpha 2-macroglobulin on secretion of proteinase and plasminogen inhibitors from peripheral mononuclear cells].
Zhabin SG; Zorin NA; Musatov MI
Vopr Med Khim; 1995; 41(3):34-7. PubMed ID: 8585176
[TBL] [Abstract][Full Text] [Related]
12. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
Collen D; Bounameaux H; De Cock F; Lijnen HR; Verstraete M
Circulation; 1986 Mar; 73(3):511-7. PubMed ID: 2419009
[TBL] [Abstract][Full Text] [Related]
13. Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
Monassier JP; Hanssen M
Drugs; 1987; 33 Suppl 3():247-52. PubMed ID: 2445540
[TBL] [Abstract][Full Text] [Related]
14. Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction.
Ho CH; Wang SP
Thromb Res; 1990 May; 58(3):331-41. PubMed ID: 1693793
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
16. Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.
Silence K; Collen D; Lijnen HR
Blood; 1993 Aug; 82(4):1175-83. PubMed ID: 7688990
[TBL] [Abstract][Full Text] [Related]
17. Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment--the problem of the alpha 2-antiplasmin determination.
Noll G; Lämmle B; Duckert F
Thromb Haemost; 1984 Jul; 51(3):334-7. PubMed ID: 6238441
[TBL] [Abstract][Full Text] [Related]
18. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy.
Mohler MA; Refino CJ; Chen SA; Chen AB; Hotchkiss AJ
Thromb Haemost; 1986 Oct; 56(2):160-4. PubMed ID: 2433785
[TBL] [Abstract][Full Text] [Related]
19. Plasmin inhibitors in different fibrinolytic treatment patterns.
Lasierra J; Diez M; Perera C; Viladés E
Haemostasis; 1981; 10(1):51-62. PubMed ID: 6162721
[TBL] [Abstract][Full Text] [Related]
20. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors.
Walker JB; Bajzar L
J Thromb Haemost; 2007 Jun; 5(6):1257-64. PubMed ID: 17389009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
